Durect says FDA starts review of surgery pain drug

Durect says FDA is reviewing long-lasting surgery pain drug Posidur, with decision due in Feb.

Associated Press

CUPERTINO, Calif. (AP) -- Durect Corp. said Thursday the Food and Drug Administration is now reviewing its drug Posidur, and will make a decision on the post-surgery pain treatment in February.

Posidur is a single injection designed to relieve pain for up to three days after surgery. Durect said the FDA accepted its marketing application and intends to make a ruling by Feb. 12.

Shares of Durect picked up 9 cents, or 10.6 percent, to 92 cents in morning trading.

Durect also developed the painkiller Remoxy, which is designed to be harder to abuse. Pfizer Inc. has a license to Remoxy, but its efforts to get marketing approval have been delayed for years. Pfizer said in May that it may not pursue further development.

View Comments (6)